{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-026714","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2025-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.739325+00:00","generated_at":"2026-05-24T08:39:11.140210+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Annovis Bio reports Q4/FY2024 results; launches Phase 3 AD trial with data expected mid-2026","bullets":["Q4 net loss $0.43/share vs $2.24 YoY; FY net loss $2.02 basic, $2.31 diluted vs $6.23 in 2023.","Cash $10.6M at Dec 31, 2024; after $21M stock offering, runway extends to Q4 2025.","Phase 3 early AD trial launched Feb 2025; symptomatic data expected mid-2026, disease-modifying data mid-2027.","FDA cleared Phase 3 early AD trial Oct 2024 based on Phase 2/3 data showing symptomatic improvement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-026714","json":"https://secwatch.observer/filing/0001104659-25-026714.json","markdown":"https://secwatch.observer/filing/0001104659-25-026714.md","text":"https://secwatch.observer/filing/0001104659-25-026714.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465925026714/0001104659-25-026714-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465925026714/tm2510031d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T08:39:11.140210+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}